Showing results (31-40 of 105) with videos related to

Sort By:
Pageof 11
Journal of Nanoscience and Nanotechnology|February 21, 2013
Novel nanoparticles formulation for cassette dosing via intravenous injection in rats for high throughput pharmacokinetic screening and potential applicationsPo-Chang Chiang, Yuzhong Deng, Savita Ubhayaka, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 12, 2010
Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941Laurent Salphati, Harvey Wong, Marcia Belvin, et al.
Nanoscale Research Letters|April 2, 2014
Nanosuspension delivery of paclitaxel to xenograft mice can alter drug disposition and anti-tumor activityPo-Chang Chiang, Stephen Gould, Michelle Nannini, et al.
Frontiers in Pharmacology|March 18, 2024
Neutrophil elastase as a versatile cleavage enzyme for activation of αvβ3 integrin-targeted small molecule drug conjugates with different payload classes in the tumor microenvironmentAnne-Sophie Rebstock, Mareike Wiedmann, Beatrix Stelte-Ludwig, et al.
Biomedical Chromatography : BMC|February 8, 2012
Validation and application of a liquid chromatography-tandem mass spectrometric method for the determination of GDC-0834 and its metabolite in human plasma using semi-automated 96-well protein precipitationYoung G Shin, Steve A Jones, Stan C Murakami, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|February 13, 2009
Hepatobiliary disposition of thyroid hormone in Mrp2-deficient TR- rats: reduced biliary excretion of thyroxine glucuronide does not prevent xenobiotic-induced hypothyroidismLloyd Lecureux, Matthew Z Dieter, David M Nelson, et al.
Clinical Pharmacokinetics|September 17, 2014
Physiologically based pharmacokinetic modeling as a tool to predict drug interactions for antibody-drug conjugatesYuan Chen, Divya Samineni, Sophie Mukadam, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|December 25, 2010
Preclinical absorption, distribution, metabolism, excretion, and pharmacokinetic-pharmacodynamic modelling of N-(4-(3-((3S,4R)-1-ethyl-3-fluoropiperidine-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorophenyl)-2-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxamide, a novel MET kinase inhibitorBianca M Liederer, Leonid M Berezhkovskiy, Brian J Dean, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2011
Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activationHarvey Wong, Bruno Alicke, Kristina A West, et al.
Cancer Research Communications|October 26, 2023
Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated TranscriptionMelanie M Frigault, Arushi Mithal, Harvey Wong, et al.
Pageof 11